ChargePoint spoke to World Pharma Today to discuss supply chain in the pharmaceutical industry and how it will be shaped by increased calls for supply chain localisation from governments worldwide.
After the closure of API manufacturing facilities at the height of the first wave of the COVID-19 pandemic resulted in severe shortages of APIs and other vital ingredients, some governments are considering incentivising drug manufacturing companies to source their raw materials more locally, instead of relying on suppliers overseas. You can read the full article here.
